ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
18 Setembro 2023 - 6:00PM
Business Wire
ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field
of antibody-drug conjugates (ADCs) for the treatment of cancer,
today announced that on September 18, 2023, and in connection with
the previously announced appointment of Ms. Lauren White as
ImmunoGen’s Senior Vice President and Chief Financial Officer, the
compensation committee of the Company’s Board of Directors (the
“Compensation Committee”) approved grants of non-qualified stock
options to purchase 295,975 shares of its common stock and
restricted stock units (“RSUs”) covering 51,625 shares of its
common stock under the Inducement Plan to Ms. White.
The Inducement Plan is used exclusively for the grant of equity
awards to individuals who were not previously employees of
ImmunoGen (or following a bona fide period of non-employment), as
an inducement material to such individual’s entering into
employment with ImmunoGen, pursuant to Rule 5635(c)(4) of the
Nasdaq Listing Rules.
The options have an exercise price of $15.71 per share, which is
equal to the closing price of ImmunoGen’s common stock on the
Nasdaq Global Select Market on September 18, 2023. Each option will
vest as to 25% of the shares underlying such option on the first
anniversary of the grant date and as to an additional 6.25% of the
shares underlying the option quarterly thereafter, subject to Ms.
White’s continued employment on each vesting date. Each RSU will
vest as to 25% of the shares underlying the RSU award on the first
anniversary of the grant date and as to an additional 25% of the
shares underlying the RSU award annually thereafter, subject to Ms.
White’s continued employment on each vesting date. Each option and
RSU is subject to the terms and conditions of the Inducement Plan
and the terms and conditions of a stock option agreement and an RSU
agreement covering the respective grants.
ABOUT IMMUNOGEN ImmunoGen is developing the next
generation of antibody-drug conjugates to improve outcomes for
cancer patients. By generating targeted therapies with enhanced
anti-tumor activity and favorable tolerability profiles, we aim to
disrupt the progression of cancer and offer our patients more good
days. We call this our commitment to TARGET A BETTER NOW™.
Learn more about who we are, what we do, and how we do it at
www.immunogen.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230918299440/en/
INVESTOR RELATIONS CONTACT ImmunoGen Anabel Chan
781-895-0600 anabel.chan@immunogen.com MEDIA CONTACTS
ImmunoGen Courtney O’Konek 781-895-0600
courtney.okonek@immunogen.com OR FTI Consulting Robert Stanislaro
212-850-5657 robert.stanislaro@fticonsulting.com
ImmunoGen (NASDAQ:IMGN)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
ImmunoGen (NASDAQ:IMGN)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024